Brief: Oncolys BioPharma plans capital alliance with bio firm in vaccine business
29/03/2017 07:35
March 29 (Reuters) - Oncolys BioPharma Inc 4588.T :
* Says the company plans to enter into a capital alliance
with University of Washington-originated bio firm Precision
Virologics Inc which is engaged in R&D of vaccine for emerging
infectious disease, in April
* Says co was granted to own right of veto regarding all
projects of Precision Virologics in Asia area
* Co will use $500,000 to acquire shares issued by Precision
Virologics, and will own about 14 percent stake in it after
transaction
* Business expects to initiate since April
Source text in Japanese: https://goo.gl/TPt2SS
Further company coverage: 4588.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 62674724;
Reuters Messaging: Cheng.Li@thomsonreuters.com@reuters.net))